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Background: Strategies to identify high risk individuals who may 
develop lung cancer are sorely needed. Radiographic screening has 
several drawbacks including cost, high false positive rate, and exclu-
sion of never-smokers who account for up to 13% of new diagnoses. 
Sputum collection can be difﬁcult in up to half of former smokers. 
Alternatively, saliva is readily available and easy to collect. We have 
previously shown high sensitivity and speciﬁcity in distinguishing 
newly diagnosed oral squamous cell carcinoma from matched controls 
(Li et al. Clin Cancer Res 2004). Others have shown a correlation of 
salivary and serum levels of soluble Her2/neu in women with breast 
cancer compared to benign tumor and healthy controls (Streckfus et al. 
Clin Cancer Res 2000). These studies led us to embark on a pilot study 
to validate mRNA expression on a gene exon array platform and to ex-
plore gene exon signatures discriminating between early-stage NSCLC 
and healthy controls. 
Methods: Saliva is currently being collected from healthy subjects ages 
40-79, (current and former smokers [≥20 pack-year] and never-smokers 
[<100 cigarettes/lifetime] and histologically-conﬁrmed, untreated stage 
I-II NSCLC patients along with a medical history questionnaire. Exclu-
sion criteria included: active pulmonary infection within 6 months, ste-
roid inhaler use ≥ 6 months, or history of other invasive cancer within 
past 5 years. A one-time saliva specimen is being obtained between 9-
10 am to avoid diurnal variation, mixed with a RNA stabilization agent, 
and stored at -70˚C. RNA is then extracted, ampliﬁed, and hybridized 
to the Affymetrix Human Exon 1.0 arrays (which contain 1.4 million 
probe sets). Array data is analyzed after appropriate normalization. 
Results: As proof-of-principal of the value of the exon array discov-
ery platform, saliva mRNA expression was performed on 18 healthy 
subjects [14 males (3 never-smokers), 11 females (8 never-smokers)]. 
All of whom were able to provide adequate sample for analysis. Our 
data demonstrate that we have successfully ampliﬁed salivary RNA, 
hybridized to the exon array and have developed the statistical and 
informatics tools to harness the diagnostic information. Using these 
developed tools and the healthy cohort of subjects, we have identiﬁed 
and validated gender-speciﬁc salivary exon signatures.
Conclusions: Preliminary results with saliva mRNA exon-level expres-
sion proﬁling suggest that quality samples are easily obtainable and 
the technique is feasible. Updated results with NSCLC specimens will 
be presented. Supported by International Association for the Study of 
Lung Cancer Fellowship Award (GJW) and R01-DE15970-03 (DTW).
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Background: Lung cancer is the most common cancer in the world, 
both in terms of incidence (1.35 million new cases, representing 12.4% 
of all new cancers) and mortality (1.18 million deaths, or 17.6% of the 
world total). Detection of lung cancer usually occurs late in the disease 
when it is beyond effective treatment and consequently, there is a high 
mortality rate. In clinically advanced tumour stages, long-term survival 
is rarely achieved with conventional cytotoxic agents. Therefore, the 
way forward for improved management and prognosis for individuals 
at high-risk lies with early detection of disease. 
Given that the causes of common cancers, such as lung cancer, may 
have their basis in environmental exposures occurring in the genetically 
predisposed host, it is essential that we study the interaction between 
lifestyle factors and susceptibility genes to produce a molecular-epi-
demiological risk assessment model. An epidemiological model has 
recently been developed by the Liverpool Lung Project (LLP) to select 
individuals at high risk of developing lung cancer. 
Aims: The Peninsula Lung Project will elucidate the role of lifestyle 
and environmental risk factors in determining speciﬁc acquired genetic 
alterations in the process leading to lung cancer, with the intention of 
developing a speciﬁc lung cancer risk assessment model for the Penin-
sula region of the UK. 
Methods: We plan to use the LLP molecular-epidemiological approach 
in a region of South West England (Peninsula), which differs from 
Liverpool in its demographic makeup. The study (which has ethical 
and NCRN approvals) will have a case-control design and will be 
conducted in 5 centres across the South West Peninsula. Each centre 
will recruit a group of newly diagnosed cases of lung cancer and a 
comparable group of either population or hospital controls. (Total: 
500 cases/1000 controls). Structured self-complete questionnaires will 
concentrate on obtaining details on lifestyle, residential history, medical 
history and occupational history over the whole life course. Whenever 
possible, place of residence will be mapped to local measures of air 
pollution. As well as tumour material from cases, samples of blood and 
oral scrapes will be collected both from cases and controls for methyla-
tion studies and SNIP analysis. Outcome data for all subjects will be 
collected.
Two controls will be selected for each case: control A will be matched 
to cases for age (± 2 years) and sex; control B will also be matched for 
smoking. 
Conclusion: This poster will expand on the objectives and methodol-
ogy of this (P-LLP) project, which will start in May 2007.
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